RTS, S

from Wikipedia, the free encyclopedia

RTS, S , also Mosquirix is a malaria vaccine that is currently in the approval process and was developed and tested by the pharmaceutical company GlaxoSmithKline in cooperation with the PATH Malaria Vaccine Initiative . The project was also sponsored by the Bill & Melinda Gates Foundation .

Admission

The vaccine received a positive evaluation by the European Medicines Agency (EMA) for use outside the EU. RTS, S would be the first effective vaccine against malaria ever, with studies showing a significant decrease in new cases among those vaccinated by 31 to 56% depending on the age of the vaccinated. The vaccine contains a protein contained in the pathogen Plasmodium falciparum , which is supposed to induce immunization and a faster defense reaction of the immune system.

Before vaccinations can begin in Sub-Saharan Africa, the World Health Organization (WHO) should issue a statement. In a press release from October 2015, the WHO pointed out the complexity of the use of the vaccine and recommended a pilot. The Global Alliance for Vaccines and Immunization (GAVI) announced in July 2016 Template: future / in 2 yearsthat it would help finance the pilot, which could run in two phases from 2017 to 2022 . The manufacturer assumes that if the financing of the pilot is secured, the first vaccinations could take place in 2018. The piloting by a program coordinated by the WHO in Ghana, Kenya and Malawi started in 2019. On the German side, Peter Kremsner from the University Hospital Tübingen is involved in the research ; The research group of Selidji Todagbe Agnandji conducts research in the hospital founded by Albert Schweitzer in Lambaréné , Gabon .

literature

  • The RTS, S Clinical Trials Partnership: First Results of Phase 3 Trial of RTS, S / AS01 Malaria Vaccine in African Children. In: New England Journal of Medicine Volume 365, No. 20, 2011, pp. 1863-1875 ( DOI: 10.1056 / NEJMoa1102287 ).
  • Kwaku Poku Asante et al .: Safety and efficacy of the RTS, S / AS01 E candidate malaria vaccine given with expanded-program-on-immunization vaccines: 19 month follow-up of a randomized, open-label, phase 2 trial. In: The Lancet Infectious Diseases Volume 11, No. 10, 2011, pp. 741-749 ( DOI: 10.1016 / S1473-3099 (11) 70100-1 ).

Source

Web links

Individual evidence

  1. ↑ PATH Malaria Vaccine Initiative welcomes positive opinion from European regulators on GSK's Mosquirix ™ (RTS, S). Path, July 23, 2015, accessed October 29, 2015 (English, press release).
  2. ↑ GSK's malaria candidate vaccine, Mosquirix ™ (RTS, S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa. GlaxoSmithKline, July 24, 2015, archived from the original on July 28, 2015 ; accessed on September 22, 2019 (English, press release).
  3. ↑ Christopher Weckwerth: World's first malaria vaccine before approval. welt.de, July 24, 2015, accessed July 26, 2015
  4. ↑ Pilot implementation of first malaria vaccine recommended by WHO advisory groups. WHO, October 23, 2015, accessed October 29, 2015 .
  5. ↑ Tania Rabesandratana: WHO experts temper malaria vaccine hopes. SciDev.Net, October 28, 2015, accessed October 29, 2015 .
  6. ↑ WHO welcomes support from Gavi for malaria vaccine pilot program. WHO, June 23, 2016, accessed October 29, 2016 (English, Information note).
  7. ↑ GSK and PATH welcome commitment by Gavi, the Vaccine Alliance, to co-fund pilot implementation program for RTS, S malaria vaccine candidate in Africa. UNITAID funding decision expected later this summer. GlaxoSmithKline, archived from the original on November 14, 2016 ; accessed on October 29, 2016 (English).
  8. ↑ Wolfgang Geissel: WHO starts pilot project for malaria vaccination. Ärztezeitung, April 30, 2019, accessed on September 21, 2019 .
  9. ↑ Agnandji working group. University Hospital Tübingen, accessed on November 27, 2017 (Tropical Medicine).